Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...
Dolby Laboratories (NYSE:DLB – Get Free Report) will likely be posting its quarterly earnings results after the market closes ...
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...
Audio technology is evolving at a rapid pace with growing investments in cutting-edge technologies and innovations. Dolby ...
A new study published in Alzheimer’s & Dementia highlights a significant step forward in diagnosing Dementia with Lewy Bodies ...
Reports Q1 revenue $357M, consensus $345.44M. “We are off to a strong start for FY25,” said Kevin Yeaman, President and CEO, Dolby (DLB) ...